Skip to main content
. 2016 Feb;23(6):520–577. doi: 10.2174/0929867323666151223095839

Fig. (1).

Fig. (1)

Dihydrofolate reductase (DHFR) inhibitors aminopterin and methotrexate (1) and trimethoprim (2) developed for anticancer and antibacterial therapy, respectively. Aminopterin and methotrexate also possess DHFR-based antibacterial activity, while trimethoprim is selective for bacterial DHFR.